SPARC, Sun Pharmaceutical ink licensing agreement

09 Nov 2022 Evaluate

Sun Pharma Advanced Research Company (SPARC) and Sun Pharmaceutical Industries have inked licensing agreement for commercialization of benzyl alcohol and propylene glycol-free phenobarbital sodium powder for injection in the United States. SPARC submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (US FDA) for this product for the treatment of neonatal seizures in February 2022.

Currently, there are no phenobarbital injection products approved by the USFDA for the treatment of seizures in newborns. Under the terms of the license agreement, Sun Pharma will pay SPARC an upfront payment of $10 million. SPARC will also be eligible to receive milestone payments contingent upon the achievement of regulatory and sales milestones, as well as tiered royalties on sales.

SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.

Sun Pharma Adv. Res Share Price

129.35 0.80 (0.62%)
22-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 592.15
Indegene 475.10
CMS Info Systems 327.30
Sagility 52.46
Smartworks Coworking 438.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×